RVL Pharmaceuticals plc (RVLPQ)

OTCMKTS: RVLPQ · Delayed Price · USD
0.0001
0.00 (0.00%)
Mar 28, 2024, 1:50 PM EDT - Market closed

Company Description

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary.

It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults.

The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022.

RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

RVL Pharmaceuticals plc
RVL Pharmaceuticals logo
Country United States
Founded 2000
Industry Biotechnology
Sector Healthcare
Employees 125

Contact Details

Address:
400 Crossing Boulevard
Bridgewater, New Jersey 08807
United States
Phone (908) 809-1300

Stock Details

Ticker Symbol RVLPQ
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001739426
SIC Code 2834

Key Executives

Name Position
Brian A. Markison Chairman, President, Chief Executive Officer and Principal Financial Officer
James D. Schaub Executive Vice President and Chief Operating Officer
Christopher A. Klein General Counsel
Michael J. DePetris Principal Accounting Officer
Jarret Miller Executive Vice President of Human Resources
Scott Schroppe Secretary

Latest SEC Filings

Date Type Title
Feb 13, 2024 8-K Current Report
Jan 17, 2024 8-K Current Report
Dec 20, 2023 8-K Current Report
Nov 28, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 27, 2023 8-K Current Report
Nov 20, 2023 25-NSE Filing
Nov 16, 2023 DEF 14A Other definitive proxy statements
Nov 6, 2023 PRE 14A Other preliminary proxy statements
Nov 6, 2023 8-K Current Report
Nov 1, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership